CRC biomarkers: metastases have high concordance

  • EBioMedicine

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Liver and lung metastases of colorectal cancer (CRC) have a high concordance with the primary tumor for biomarker analysis.
  • More research needs to be performed to determine concordance between peritoneal metastases and primary tumors.

Why this matters

  • The primary tumor cannot always be accessed for biopsy.

Study design

  • Meta-analysis of 61 articles (n=3565). Included studies: liver (53 studies; n=2276), lymph nodes (30 studies; n=1123), lung (37 studies; n=438), peritoneum (17 studies; n=132).
  • Funding: None disclosed.

Key results

  • Median concordances between metastatic site and primary tumor:
    • KRAS: 93.7% (range, 67%-100%).
    • NRAS: 100% (90%-100%).
    • BRAF: 99.4% (80%-100%).
    • PIK3CA: 93% (42%-100%).
    • TIP53: 92.9% (73%-100%).
  • Pooled discordances:
    • KRAS: 8% (95% CI, 5%-10%).
    • BRAF: 8% (95% CI, 5%-10%).
    • PIK3CA: 7% (95% CI, 2%-13%).
    • Overall: 28% (95% CI, 14%-44%).
    • There was publication bias in the KRAS and BRAF studies (Egger's test: P=.01 for both).
  • The median absolute concordance in multiple biomarkers was 81% (95% CI, 5%-95%).

Limitations

  • Included studies were retrospective and had limited sample sizes.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit